Chimeric Therapeutics Limited has released a press release.
CHM ceases enrolment in Phase 1 trial and Company update
Earlier from Chimeric Therapeutics
- Chimeric receives $1.62M advance on FY26 R&D tax incentive
- CHM CDH17 Phase 1 clinical trial update - New DL 3 data
- Appointment of Financial Adviser for Strategic Review
- CHM announces positive Phase 1/2 data at ASCO